Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Inhibikase Therapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- +1 vs. Q4 2023
- Shares held
- 205.6K
- −29.4K (−12.5%) vs. Q4 2023
- Total value
- $443.8K
- +$144.9K (+48.5%) vs. Q4 2023
- New holders
- 3
- 2 more added
- Sold out
- 2
- 4 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Wells Fargo & Company | 207 | $447 | 0.00% | +6+3.0% | Added |
| Morgan Stanley | 1,667 | $3.60K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 2,000 | $4.32K | 0.00% | +2,000 | New |
| Tower Research Capital LLC (TRC) | 2,771 | $5.99K | 0.00% | −3,148−53.2% | Reduced |
| UBS Group AG | 3,214 | $6.94K | 0.00% | +3,214 | New |
| State Street Corp | 10,084 | $21.8K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 16,724 | $36.1K | 0.00% | −65,321−79.6% | Reduced |
| Redmond Asset Management, LLC | 19,560 | $42.3K | 0.01% | −84−0.4% | Reduced |
| Renaissance Technologies LLC | 21,422 | $46.0K | 0.00% | −3,000−12.3% | Reduced |
| Susquehanna International Group, LLP | 22,616 | $48.9K | 0.00% | +22,616 | New |
| Geode Capital Management, LLC | 28,692 | $62.0K | 0.00% | 00.0% | Unchanged |
| Blair William & Co | 76,601 | $165.5K | 0.00% | +16,333+27.1% | Added |
| Royal Bank of Canada | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −62−100.0% | Sold out |